APATINIB for Hepatocellular carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 6 adverse event reports in the FDA FAERS database where APATINIB was used for Hepatocellular carcinoma.
Most Reported Side Effects for APATINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Myelosuppression | 30 | 19.4% | 2 | 9 |
| Palmar-plantar erythrodysaesthesia syndrome | 28 | 18.1% | 5 | 1 |
| Proteinuria | 23 | 14.8% | 3 | 0 |
| Fatigue | 22 | 14.2% | 4 | 1 |
| Rash | 21 | 13.6% | 3 | 2 |
| Hypertension | 20 | 12.9% | 3 | 1 |
| Anaemia | 19 | 12.3% | 5 | 0 |
| Diarrhoea | 17 | 11.0% | 2 | 2 |
| Decreased appetite | 15 | 9.7% | 4 | 1 |
| Leukopenia | 15 | 9.7% | 1 | 0 |
| Disease progression | 14 | 9.0% | 4 | 0 |
| Nausea | 13 | 8.4% | 3 | 1 |
| Thrombocytopenia | 13 | 8.4% | 2 | 1 |
| Platelet count decreased | 12 | 7.7% | 1 | 4 |
| Pyrexia | 11 | 7.1% | 1 | 1 |
Other Indications for APATINIB
Hepatic cancer (18)
Gastric cancer (12)
Non-small cell lung cancer (11)
Breast cancer (7)
Adenocarcinoma gastric (5)
Breast cancer metastatic (5)
Metastases to central nervous system (5)
Serous cystadenocarcinoma ovary (5)
Other Drugs Used for Hepatocellular carcinoma
ATEZOLIZUMAB (8,443)
BEVACIZUMAB (7,773)
LENVATINIB (5,384)
SORAFENIB (4,986)
CABOZANTINIB S-MALATE (2,670)
DURVALUMAB (1,255)
NIVOLUMAB (1,142)
REGORAFENIB (1,050)
TREMELIMUMAB\TREMELIMUMAB-ACTL (589)
PEMBROLIZUMAB (518)